secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021225
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics Q1 2023 net loss $18.4M; cash $171M; BDC-1001 Phase 2 plans
--------------------------------------------------------------------------------

- Net loss from operations $18.4M vs $23.9M in Q1 2022; collaboration revenue $1.8M (up from $0.8M).
- Cash, equivalents, and marketable securities $171.0M as of March 31, 2023; expected to fund operations through 2025.
- R&D expenses $14.6M (down from $18.4M) due to lower manufacturing and pipeline reprioritization.
- BDC-1001 Phase 2 program to initiate in 2023 in HER2+ colorectal, endometrial, gastroesophageal, and breast cancer.
- Comprehensive BDC-1001 safety/efficacy data to be presented at ASCO 2023 on June 3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000095017023021225/0000950170-23-021225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000095017023021225/bolt-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer